QPS LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$223,795	6
2023	Research	$366,335	8
2022	Research	$1,404,659	24
2021	Research	$968,898	13
2019	Research	$1,011,555	3

Breakdown

Who paid Research payments · program years 2019–2024

Vanda Pharmaceuticals Inc. $2,574,410 38 payments
Merck Sharp & Dohme Corporation $1,011,555 3 payments
GlaxoSmithKline, LLC. $389,276 13 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of V172 in Healthy Younger Participants Ages 18 and 49 Years and Healthy Older Participants Ages 60 and 79 Years $1,011,555 3 payments
Study to Evaluate the Effect of Food on Vhx-896 in Healthy Volunteers $639,067 12 payments
An Open Label, Two-Period, Two-Way Crossover Study to Evaluate the Pharmacokinetics of A Single Dose of the Capsule Formulation of Tradipitant in Healthy Participants in A Fed and Fasted State. $600,804 10 payments
An Open-Label, Two-Period, Randomized, Single Oral Dose, Crossover Study to Evaluate the Bioequivalence of 20 MG Tasimelteon Capsule Formulation Relative to 5 ML Tasimelteon Liquid Suspension Formulation in Healthy Volunteers $596,202 4 payments
Bioequivalence Study Between Vhx-896 Tablets and Iloperidone Tablets in Healthy Volunteers $562,517 10 payments
Study name not reported $270,867 2 payments
An Open-Label, Two-Period, Randomized, Single Oral Dose, Crossover Study to Evaluate the Bioavailability of 5 ML Tradipitant Liquid Suspension Formulation Relative to 85 MG Tradipitant Capsule Formulation in Healthy Volunteers $175,821 2 payments
A Phase III, Observer-Blind, Randomized, Multi-Country Study to Evalua $118,409 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.